详情页

资源类型：

文章类型：

作者：

Zhi-Ming Shao[1] * ; Jihui Hao[2] ; Shui Wang[3] ; Qingyuan Zhang[4] ; Yuanting Gu[5] ; Fuguo Tian[6] ; Shouman Wang[7] ; Quchang Ouyang[8] ; Longzhen Zhang[9] ; Yunjiang Liu[10]

; Jing Cheng[11] ; Shundong Cang[12] ; Zhenzhen Liu[13] ; Chunsen Xu[14] ; Jianyun Nie[15] ; Ye Lv[16] ; Jun Qian[17] ; Ting Wang[18] ; Mengzhu Yu[19] ; Fei Wu[19] ;

机构： [1]Fudan University Shanghai Cancer Center, Shanghai, China [2]Tianjin Medical University Cancer Institute and Hospital, Tianjin, China [3]Jiangsu Province Hospital/The First Affiliated Hospital of Nanjing Medical University, Nanjing, China [4]Harbin Medical University Cancer Hospital, Harbin, China [5]The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China [6]Shanxi Provincial Cancer Hospital, Taiyuan, China [7]Xiangya Hospital of Central South University, Changsha, Hunan, China [8]Hunan Cancer Hospital, Changsha, China [9]The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China [10]The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei Province, China [11]Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Changchun, China [12]Henan Provincial People's Hospital, Zhengzhou, China [13]Henan Breast Cancer Center, Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, China [14]Fujian Medical University Union Hospital, Fuzhou, China [15]Yunnan Cancer Hospital, Kunming, China [16]General Hospital of Ningxia Medical University, Yinchuan, China [17]The First Affiliated Hospital of Bengbu Medical University, Bengbu, China [18]The First Affiliated Hospital, Air Force Medical University, Xian, China [19]Jiangsu Hengrui Pharmaceuticals Co., Ltd., Shanghai, China

出处：

DOI：

ISSN：

基金：

语种：

WOS：

中科院分区：

出版当年[2025]版：

大类 | 1 区

医学

小类 | 1 区肿瘤学

最新[2025]版：

大类 | 1 区

医学

小类 | 1 区肿瘤学

JCR分区：

出版当年[2024]版：

Q1 ONCOLOGY

最新[2024]版：

Q1 ONCOLOGY

第一作者：

第一作者机构： [1]Fudan University Shanghai Cancer Center, Shanghai, China

推荐引用方式(GB/T 7714)：

APA：

MLA：

Dalpiciclib (Dalp) plus endocrine therapy (ET) as adjuvant treatment for HR+/HER2-early breast cancer (BC): The randomized, phase 3, DAWNA-A trial

文献详情